Literature DB >> 15019041

Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process.

Y H Han1, H X Lou, D M Ren, L R Sun, B Ma, M Ji.   

Abstract

A separation method for the hepatoprotective drug silybin and its metabolites by RP-HPLC was described. Based on this separation, the stereoselectivity of the metabolism of silybin was investigated by incubation of the drug and its two diastereoisomers with bovine liver microsomes. Information about the structures of these metabolites was obtained, using UV, HPLC/MS and NMR spectra. Four major metabolites (M(1), M(4) of silybin A and M(2), M(5) of silybin B), were prepared by preparative HPLC, and their configurations were accomplished by NMR spectra. A HPLC method was used to quantify the metabolites. The results showed that silybin was extensively metabolized and the major sites for glucuronidation were the C-20, C-7, at phenolic OH groups. Furthermore, the results obtained reveal that there was significant stereoselectivity in the glucuronidation process of silybin. Silybin B was glucuronidated at a more efficient rate than its diastereoisomer, and glucuronidation of silybin B was much preferred at the 20 position, while that of silybin A was similar at both 7 and 20 position.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019041     DOI: 10.1016/j.jpba.2003.12.002

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  10 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.

Authors:  Brandon T Gufford; Tyler N Graf; Noemi D Paguigan; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-08-27       Impact factor: 3.922

3.  Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Authors:  Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

Review 4.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives.

Authors:  Peter F Surai
Journal:  Antioxidants (Basel)       Date:  2015-03-20

Review 5.  Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.

Authors:  Michal Bijak
Journal:  Molecules       Date:  2017-11-10       Impact factor: 4.411

6.  Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.

Authors:  Ying Xie; Sonia R Miranda; Janelle M Hoskins; Roy L Hawke
Journal:  Molecules       Date:  2017-01-15       Impact factor: 4.411

7.  The Effect of Silymarin Flavonolignans and Their Sulfated Conjugates on Platelet Aggregation and Blood Vessels Ex Vivo.

Authors:  Jana Pourová; Lenka Applová; Kateřina Macáková; Marie Vopršalová; Thomas Migkos; Roger Bentanachs; David Biedermann; Lucie Petrásková; Václav Tvrdý; Marcel Hrubša; Jana Karlíčková; Vladimír Křen; Kateřina Valentová; Přemysl Mladěnka
Journal:  Nutrients       Date:  2019-09-24       Impact factor: 5.717

Review 8.  Metabolism, Transport and Drug-Drug Interactions of Silymarin.

Authors:  Ying Xie; Dingqi Zhang; Jin Zhang; Jialu Yuan
Journal:  Molecules       Date:  2019-10-14       Impact factor: 4.411

9.  Inhibition of Lysozyme Amyloid Fibrillation by Silybin Diastereoisomers: The Effects of Stereochemistry.

Authors:  Xuanyu Chen; Xiaomin Deng; Xingxing Han; Yinmei Liang; Zhiping Meng; Rui Liu; Wenqiang Su; Huaxu Zhu; Tingming Fu
Journal:  ACS Omega       Date:  2021-01-20

Review 10.  Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer.

Authors:  Maryam Fallah; Amirhossein Davoodvandi; Shahin Nikmanzar; Sarehnaz Aghili; Seyed Mohammad Ali Mirazimi; Michael Aschner; Amir Rashidian; Michael R Hamblin; Mohsen Chamanara; Navid Naghsh; Hamed Mirzaei
Journal:  Biomed Pharmacother       Date:  2021-08-13       Impact factor: 6.529

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.